Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 22, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on August 18, 2005:
- Previous Holding: 18,475,789 Ordinary Share ADRs
- New Holding: 18,454,171 Ordinary Share ADRs
- Net Change: Decrease of 21,618 ADRs
- Average Price: $47.88
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held within this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the impact of the 21,618 ADR reduction on the total outstanding share count of the US Retirement Savings Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in holdings on August 18, 2005.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure the notification scope is complete.
- Check subsequent filings for any further changes in the holdings of Dr. J P Garnier and Dr. T Yamada related to this fund.